Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Pediatric sarcomas: challenges and opportunities.
Journal: Genes & development
Published: August 04, 2026
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.
Journal: Future oncology (London, England)
Published: June 19, 2026
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 02, 2022
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
Journal: Cancers
Published: April 27, 2021
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Journal: Seminars in hematology
Published: September 30, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Journal: Blood cancer journal
Published: November 22, 2019
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 13, 2018
Daratumumab proves safe and highly effective in AL amyloidosis.
Journal: British journal of haematology
Published: June 26, 2018
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Journal: Leukemia
Published: September 29, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 12, 2017
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.
Journal: Journal of hematology & oncology
Published: August 25, 2016
Last Updated: 09/26/2026